Bioversys Sas
Clinical trials sponsored by Bioversys Sas, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Drug interaction study launches: will BV100 change how polymyxin b works? Results expected Sep 2026 (estimated)
-
New antibiotic cocktail takes on superbug pneumonia in hospitals
Disease control Recruiting nowThis phase 3 trial tests a new antibiotic combination (BV100 plus low-dose polymyxin B) against a standard treatment (colistin plus ampicillin/sulbactam) for hospital-acquired or ventilator-associated pneumonia caused by a drug-resistant bacteria called CRABC. The study will enro…
Phase 3 • Sponsor: BioVersys SAS • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Drug interaction study launches: will BV100 change how polymyxin b works?
Knowledge-focused Recruiting nowThis early-stage trial is testing whether a new drug called BV100 changes how the body processes the antibiotic polymyxin B. Sixteen healthy adults will receive polymyxin B alone and then again with BV100 to compare drug levels. The goal is not to treat disease but to gather safe…
Phase 1 • Sponsor: BioVersys SAS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC